Currently, there are 111.57M common shares owned by the public and among those 108.10M shares have been available to trade.
The company’s stock has a 5-day price change of 15.49% and -30.63% over the past three months. VKTX shares are trading -15.33% year to date (YTD), with the 12-month market performance down to -4.67% lower. It has a 12-month low price of $28.64 and touched a high of $99.41 over the same period. VKTX has an average intraday trading volume of 3.83 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.43%, -8.90%, and -37.49% respectively.
Institutional ownership of Viking Therapeutics Inc (NASDAQ: VKTX) shares accounts for 74.25% of the company’s 111.57M shares outstanding.
It has a market capitalization of $3.80B and a beta (3y monthly) value of 0.87. The earnings-per-share (ttm) stands at -$1.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.17% over the week and 7.13% over the month.
Earnings per share for the fiscal year are expected to decrease by -57.98%, and -35.26% over the next financial year.
Looking at the support for the VKTX, a number of firms have released research notes about the stock. Scotiabank stated their Sector Outperform rating for the stock in a research note on February 13, 2025, with the firm’s price target at $102. Citigroup coverage for the Viking Therapeutics Inc (VKTX) stock in a research note released on February 07, 2025 offered a Neutral rating with a price target of $38. Piper Sandler was of a view on December 02, 2024 that the stock is Overweight, while B. Riley Securities gave the stock Buy rating on November 22, 2024, issuing a price target of $109. H.C. Wainwright on their part issued Buy rating on November 04, 2024.
